Loading color scheme

News

Virtici Announces Funding from NIH to Develop a New Treatment for Periodontal Disease

Seattle, Washington - Virtici LLC announced today that the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) award to advance VTC-886, a first-in-class small molecule for the prevention of P. gingivalis infection.

Read more

Rise Therapeutics Begins Operations of its GMP Manufacturing Facility

Rockville, MD. Rise Therapeutics announced today that they have successfully initiated operations of their GMP manufacturing facility based in Rockville, MD.  Funding to help set up this GMP manufacturing operation came from the National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program Grant, which assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants. Launching of operations for this facility was also supported by the financial contributions of the Montgomery County Economic Development Corporation.  

Read more

Rise Therapeutics Announces Publication of an Important Peer-Reviewed Journal Article Related to its R-3750 Program

Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, announced today the publication of the co-authored article, “Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire” in the journal Biomedicines.

Read more

Rise Therapeutics Announces New Funding to Support Clinical Development of its Oral Anti-Inflammatory Drug for Inflammatory Bowel Disease

Rockville, MD. Rise Therapeutics announced today that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institute of Health’s (NIH) to support proof-of-concept clinical testing of their lead therapeutic candidate, R-3750. R-3750 is synthetic biology-based immune cellular medicine being developed for the treatment of Inflammatory Bowel Disease (IBD).

Read more

Aclys Bio and Genmab Enter Research and Commercial License Option Agreement to Develop Proprietary Aclys Antibodies Against an Undisclosed Target

Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

Read more

Scioto Biosciences Doses First Patient in Autistic Disorder Study

Earlier this month, Scioto Biosciences, Inc. began their Phase Ib clinical trial of SB-121 for the treatment of Autistic DIsorder (AD). 

Read more